Analysts embrace Lilly cancer candidate
October 15 2012
Analysts are excited about Lilly's experimental cancer drug, ramucirumab, despite few details.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.